Breaking News Instant updates and real-time market news.

ALNY

Alnylam

$92.88

1.32 (1.44%)

10:56
11/10/19
11/10
10:56
11/10/19
10:56

Alnylam initiates Phase 3 study of lumasiran, reports 'positive' Phase 2 data

Alnylam Pharmaceuticals announced that the company has initiated ILLUMINATE-C, a new global Phase 3 study of lumasiran, an investigational, subcutaneously administered RNAi therapeutic in development for the treatment of primary hyperoxaluria type 1. The study will enroll patients of all ages with advanced renal disease, and the primary study endpoint is the percent reduction in plasma oxalate from baseline to six months. Alnylam expects to report initial ILLUMINATE-C results in late 2020. The company also announced new positive efficacy results from the ongoing Phase 2 open-label extension study of lumasiran, which were presented at the American Society of Nephrology 2019 Annual Meeting on Saturday, November 9. Pritesh Gandhi, PharmD, VP and General Manager, Lumasiran program at Alnylam. "We are also pleased to report new results from our Phase 2 OLE study, and are encouraged by the sustained reductions in urinary oxalate and by the overall safety profile of lumasiran observed to date."

  • 13

    Nov

  • 18

    Nov

  • 07

    Dec

  • 04

    Feb

ALNY Alnylam
$92.88

1.32 (1.44%)

09/02/19
PIPR
09/02/19
NO CHANGE
Target $145
PIPR
Overweight
Alnylam price target raised to $145 from $142 at Piper Jaffray
Piper Jaffray analyst Edward Tenthoff raised his price target for Alnylam (ALNY) to $145 from $142 after partner The Medicine Co. (MDCO) presented positive Phase III ORION-11 data on inclisiran in 1,617 ASCVD patients at the European Society of Cardiology Congress in Paris. The analyst remains confident in inclisiran approval next year and Alnylam is eligible for milestones plus up to double-digit royalties. He reiterates an Overweight rating on Alnylam shares.
09/03/19
STFL
09/03/19
NO CHANGE
Target $116
STFL
Buy
Alnylam data broadly support inclisiran as approvable drug, says Stifel
After Alnylam (ALNY) partner The Medicine Co. (MDCO) presented Phase 3 data on inclisiran at the European Society of Cardiology Congress, Stifel analyst Paul Matteis said the efficacy data were positive, but the focus is really on safety and "encouragingly" the adverse events, incidence of death, and serious adverse events all occurred at similar rates on inclisiran versus placebo. The analyst, who believes the data broadly support inclisiran as an approvable drug, also thinks the results validate Alnylam's recent efforts in non-orphan areas. Matteis, who noted that Alnylam will receive up to a 20% royalty on inclisiran sales, has a Buy rating and $116 price target on Alnylam shares.
09/10/19
PIPR
09/10/19
NO CHANGE
Target $145
PIPR
Overweight
Alnylam's updated OLE data shows reduced 'daily worst pain,' says Piper Jaffray
Piper Jaffray analyst Edward Tenthoff reiterated an Overweight rating and $145 price target on Alnylam after the company presented new results from the Phase III ENVISION trial and Phase I/II OLE study of givosiran in Acute Hepatic Poprphyria at the International Congress on Porphyrins and Porphyrias Conference. Tenthoff says the updated OLE data showed that monthly givosiran dosing reduced median annualized attack rate to 0.22 over 30 months, and patient reported outcomes also revealed reduced "daily worst pain" for subjects receiving givosiran, lower use of opioids and improved quality of life. Tenthoff tells investors in a research note that he is "confident" in FDA approval by the February 4 PDUFA date.
11/01/19
RAJA
11/01/19
UPGRADE
Target $24
RAJA
Outperform
Intellia Therapeutics upgraded to Outperform at Raymond James
Raymond James analyst Steven Seedhouse upgraded Intellia Therapeutics to Outperform from Market Perform with a $24 price target. In a research note to investors, Seedhouse says Intellia's NTLA-2001 is poised to benefit from the "heavy lifting" Pfizer (PFE) is doing commercially with Vyndaqel in ATTR-cardiomyopathy, adding that Intellia is also advancing manufacturing related activities in support of a Phase 1 trial for engineered cell program WT1-TCR in AML. The analyst also says Intellia's lead gene editing program, NTLA-2001 has "really good" primate data showing TTR knockdown potentially better than Alnylam's (ALNY) patisiran. He expects the market will already start to impute downstream clinical benefit for NTLA-2001 after only a few patients with initial TTR knockdown data, because of the collective data for Ionis Pharmaceuticals' (IONS) inotersen and Alnylam's patisiran showing knockdown is relevant.

TODAY'S FREE FLY STORIES

CVX

Chevron

$119.17

0.37 (0.31%)

13:39
11/22/19
11/22
13:39
11/22/19
13:39
Periodicals
Chevron plans sweeping cost-cutting, streamlining efforts, Reuters reports »

Chevon's CEO,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MET

MetLife

$49.21

0.24 (0.49%)

, ARZGY

Generali

$0.00

(0.00%)

13:33
11/22/19
11/22
13:33
11/22/19
13:33
Periodicals
Generali nearing over $3B bid for MetLife European assets, Bloomberg reports »

Assicurazioni Generali…

MET

MetLife

$49.21

0.24 (0.49%)

ARZGY

Generali

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Dec

SONO

Sonos

$15.43

1.21 (8.51%)

13:25
11/22/19
11/22
13:25
11/22/19
13:25
Options
Sonos call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NSD

NASDAQ Market Internals

$0.00

(0.00%)

13:17
11/22/19
11/22
13:17
11/22/19
13:17
Technical Analysis
NASDAQ market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NYE

NYSE Market Internals

$0.00

(0.00%)

13:16
11/22/19
11/22
13:16
11/22/19
13:16
Technical Analysis
NYSE market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BKR

Baker Hughes

$22.59

(0.00%)

13:04
11/22/19
11/22
13:04
11/22/19
13:04
Hot Stocks
Baker Hughes reports U.S. rig count down 3 to 803 rigs »

Baker Hughes reports that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BOLD

Audentes Therapeutics

$28.17

0.05 (0.18%)

13:02
11/22/19
11/22
13:02
11/22/19
13:02
Recommendations
Audentes Therapeutics analyst commentary  »

Piper remains buyer of…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SYNL

Synalloy

$13.45

(0.00%)

13:01
11/22/19
11/22
13:01
11/22/19
13:01
Hot Stocks
Synalloy board of directors decides not to make annual dividend payment »

Synalloy Corporation…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BKR

Baker Hughes

$22.60

0.01 (0.04%)

13:01
11/22/19
11/22
13:01
11/22/19
13:01
Hot Stocks
Breaking Hot Stocks news story on Baker Hughes »

Baker Hughes reports U.S.…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

WMT

Walmart

$119.65

-0.23 (-0.19%)

12:53
11/22/19
11/22
12:53
11/22/19
12:53
Periodicals
Walmart's Jet.com to stop delivering fresh groceries, CNBC reports »

Walmart's Jet.com…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SKY

Skyline

$30.99

-0.45 (-1.43%)

12:48
11/22/19
11/22
12:48
11/22/19
12:48
Recommendations
Skyline analyst commentary  »

SunTrust boosts Skyline…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

12:47
11/22/19
11/22
12:47
11/22/19
12:47
Hot Stocks
Breaking Hot Stocks news story  »

Civista Bancshares…

WE

We Company

$0.00

(0.00%)

, SFTBF

SoftBank

$0.00

(0.00%)

12:46
11/22/19
11/22
12:46
11/22/19
12:46
Periodicals
Breaking Periodicals news story on We Company, SoftBank, SoftBank »

WeWork chairman lays out…

WE

We Company

$0.00

(0.00%)

SFTBF

SoftBank

$0.00

(0.00%)

SFTBY

SoftBank

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Z

Zillow

$41.03

1.22 (3.06%)

12:45
11/22/19
11/22
12:45
11/22/19
12:45
Options
Zillow call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

12:45
11/22/19
11/22
12:45
11/22/19
12:45
General news
Breaking General news story  »

Week of 11/22…

12:45
11/22/19
11/22
12:45
11/22/19
12:45
General news
Breaking General news story  »

Week of 11/22…

12:42
11/22/19
11/22
12:42
11/22/19
12:42
Hot Stocks
Breaking Hot Stocks news story  »

Civista Bancshares…

BIIB

Biogen

$294.17

5.51 (1.91%)

12:33
11/22/19
11/22
12:33
11/22/19
12:33
Periodicals
Breaking Periodicals news story on Biogen »

Biogen settles Tecfidera…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 04

    Dec

  • 05

    Dec

BIIB

Biogen

$293.68

5.02 (1.74%)

12:26
11/22/19
11/22
12:26
11/22/19
12:26
Hot Stocks
Breaking Hot Stocks news story on Biogen »

Biogen rallies 3%, or…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 04

    Dec

  • 05

    Dec

FTCH

Farfetch

$9.73

0.335 (3.57%)

12:25
11/22/19
11/22
12:25
11/22/19
12:25
Options
Farfetch Limited call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    Dec

SPX

S&P 500

$0.00

(0.00%)

, SPY

SPDR S&P 500 ETF Trust

$310.63

0.34 (0.11%)

12:18
11/22/19
11/22
12:18
11/22/19
12:18
General news
Ray Dalio says WSJ wrong, Bridgewater not betting market will fall »

Ray Dalio, Co-Chief…

SPX

S&P 500

$0.00

(0.00%)

SPY

SPDR S&P 500 ETF Trust

$310.63

0.34 (0.11%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NSD

NASDAQ Market Internals

$0.00

(0.00%)

12:17
11/22/19
11/22
12:17
11/22/19
12:17
Technical Analysis
NASDAQ market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NYE

NYSE Market Internals

$0.00

(0.00%)

12:16
11/22/19
11/22
12:16
11/22/19
12:16
Technical Analysis
NYSE market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DELL

Dell Technologies

$53.30

-0.425 (-0.79%)

12:15
11/22/19
11/22
12:15
11/22/19
12:15
Options
Dell Technologies put volume heavy and directionally bearish »

Bearish flow noted in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Nov

  • 02

    Dec

  • 09

    Dec

  • 09

    Dec

12:15
11/22/19
11/22
12:15
11/22/19
12:15
General news
Treasury Action: the markets are mixed with no strong directional drivers »

Treasury Action: the…

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.